Key Highlights

  • Helus Pharma (NASDAQ:HELP) reported on November 16, 2026 that HLP003 met its main goal in the Phase 3 APPROACH study in major depressive disorder.
  • Depression scores fell 19.5 points on HLP003 against 11.9 on placebo at six weeks, a gap of 7.6 points, with benefits seen from day two.
  • The stock traded between USD 4.85 and USD 11.22 before the open, against a USD 8.87 prior close, and ended the session down 13.53%.
  • A second pivotal study, EMBRACE, is due to report topline results in the fourth quarter of 2027.

What the Trial Showed

APPROACH enrolled 222 adults with moderate to severe major depressive disorder whose symptoms had not responded well enough to their current antidepressant. Patients received either HLP003 or placebo in addition to their existing treatment. HLP003 is a deuterated form of psilocin, a serotonergic compound related to the active ingredient in psilocybin, which the company says is designed to promote neuroplasticity. The drug holds FDA Breakthrough Therapy Designation for this use. On the main measure, the MADRS depression scale, scores fell 19.5 points on HLP003 versus 11.9 on placebo at six weeks, a difference of 7.6 points that was highly statistically significant. The effect appeared quickly, with a 5.0 point gap on day two, and held at 12 weeks with a 7.0 point gap. At six weeks, 56.3% of HLP003 patients responded to treatment versus 28.2% on placebo, and 50.9% reached remission versus 18.2%. Those are strong numbers for a population that has already failed at least one standard antidepressant. The company reported three serious adverse events related to treatment and said no new safety signals emerged.

Why the Stock Fell Anyway

The trading pattern was extreme. Shares swung between USD 4.85 and USD 11.22 before the market opened, compared with a USD 8.87 close on November 13. They rose about 15% early, fell about 30% at one point, briefly turned positive and then sold off again to finish 13.53% lower. No single explanation was given. Several factors are likely at play. Expectations were high going into the readout, so some investors sold on the news, a common pattern when a widely anticipated result arrives. The three treatment-related serious adverse events, while limited, may have raised questions about how regulators will view safety for a drug in this class, which typically requires supervised dosing. Investors may also be weighing the cost and practicality of in-clinic treatment against oral antidepressants. Finally, the result was released on a day of heavy selling in growth stocks, with the Nasdaq Composite down 2.49%, which made it harder for speculative names to hold gains. Thin premarket Liquidity can also exaggerate swings when a large Volume of orders hits at once.

What Comes Next for HLP003

One positive Phase 3 trial is usually not enough for approval in depression. The company is running a second pivotal study, EMBRACE, with topline results expected in the fourth quarter of 2027, and an extension study called EXTEND that tracks long-term safety, durability and repeat dosing. Those studies will shape the eventual filing package, and the company has not yet given a date for a new drug application. The size of the effect seen in APPROACH gives the program a solid base, especially the early onset and the remission rates. The key questions for investors are whether EMBRACE confirms the benefit, how often patients need repeat doses, and what monitoring regulators will require. Funding is also a consideration, since late-stage psychiatry trials are costly and a sell-off makes raising Capital more expensive. The Volatility seen on November 16 suggests the stock will remain sensitive to any further detail released at medical meetings or in regulatory updates.

Where Things Stand

Helus delivered a clearly positive Phase 3 result, yet the stock closed lower after a chaotic session. The market appears focused on safety, practicality and the need for a second trial. EMBRACE results in late 2027 are the next major test.